On Thursday, Inuvo Inc (NYSEMKT:INUV)’s shares declined -20.07% to $2.31.
Inuvo Inc (INUV) a digital publishing and advertising technology company, recently declared its advertising contract with Yahoo! will renew under the same terms and conditions upon its anniversary on April 24, 2015.
Inuvo, Inc., together with its auxiliaries, operates as an Internet marketing and technology company that delivers advertisements through various networks of Websites and applications reaching desktop and mobile devices in the United States.
Xueda Education Group (ADR) (NYSE:XUE)’s shares dropped -19.29% to $2.97.
Xueda Education Group (ADR) (XUE) a leading national provider of personalized tutoring services for primary and secondary school students in China, recently declared that the Company filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2014 with the Securities and Exchange Commission on March 31, 2015.
The Company’s annual report on Form 20-F contains its audited merged financial statements and is accessible on the Company’s website at http://ir.xueda.com. The Company will provide a hard copy of its annual report free of charge to its shareholders and ADS holders upon request.
Xueda Education Group provides private personalized tutoring services for primary and secondary school students in the People’s Republic of China. The companys services comprise assessment, consultation, formulation of a customized study plan, personalized tutoring, delivery of student-oriented supporting services, and results.
At the end of Thursday’s trade, Pernix Therapeutics Holdings Inc (NASDAQ:PTX)‘s shares dipped -16.35% to $8.34.
Pernix Therapeutics Holdings Inc (PTX) a specialty pharmaceutical company, recently updated its full-year 2015 net sales guidance and business outlook.
The Company anticipates net sales for the three-months ended March 31, 2015, will be between $32 million and $35 million, contrast with $19 million for the same period in 2014.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product comprise CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product.
Novogen Limited (ADR)(NASDAQ:NVGN), ended its Thursday’s trading session with -12.15% loss, and closed at $6.94.
Novogen Limited (ADR) (NVGN) declared that it had signed a Memorandum of Understanding with the Feinstein Institute for Medical Research (‘Feinstein Institute’) of New York to collaborate with the objective of developing effective treatments for brain cancers.
The partnership brings together the drug discovery expertise of Novogen and the preclinical and clinical expertise of the Feinstein Institute in neurosciences and oncology.
Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which comprise super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
